For example, in patients with melanoma and CRC patients with elevated TMB who did not respond to anti-PD-1 therapy, homozygous loss-of-function mutations in JAK1/2 were identified, which resulted in deficient PD-L1 expression and reduced T-cell infiltration [330]. This evidence concerns the gene JAK1 and melanoma.